Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
CORCEPT THERAPEUTICS INC
Bear Case (25th pct.)
-93.7% vs price
Base Case (Median)
-93.6% vs price
Bull Case (75th pct.)
-92.0% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $3.01 | -97.5% | High (40%) |
| PE Comparable | $9.43 | -92.1% | Medium (25%) |
| Growth Trajectory DCF | $9.58 | -91.9% | Medium (20%) |
| Graham Number | $7.62 | -93.6% | Medium (40%) |
| EV/EBITDA | $7.50 | -93.7% | Medium (20%) |
| EV/FCF | $21.38 | -82.0% | Medium (20%) |
| Earnings Power Value | $7.45 | -93.7% | Medium (50%) |
Based on 7 out of 7 methods, CORT appears overvalued at the current price of $118.90. The base case fair value of $7.62 implies 93.6% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.